The World Health Organization (WHO) has called on countries to make the groundbreaking HIV prevention drug lenacapavir widely available in pharmacies and clinics. UN News Center reports that describing it as a major advancement in the fight against HIV/AIDS, WHO officials believe the injectable treatment could significantly reduce new infections, particularly among high-risk populations.
Lenacapavir is a long-acting antiretroviral injection administered just twice a year, offering a powerful alternative to daily pills and other short-duration preventive methods. “Although an HIV vaccine is still unavailable, lenacapavir is the best tool we currently have. Studies show it can prevent nearly all infections among high-risk individuals,” said WHO Director-General Tedros Adhanom Ghebreyesus.
The push for broader access comes amid global funding shortfalls in HIV prevention efforts. WHO is advocating for national programs to adopt lenacapavir and prioritize cost-effective approaches like rapid HIV testing over complex and expensive procedures.
While the U.S. approved lenacapavir in June, access remains limited outside clinical trials. WHO also continues to recommend other prevention methods such as daily oral PrEP, the bimonthly injectable cabotegravir, and the dapivirine vaginal ring.
In response to budget cuts—including reductions to PEPFAR, the largest U.S.-funded HIV program—WHO has issued new guidance on essential HIV services. “We have the tools and knowledge to end AIDS. What we need now is bold action to implement these recommendations with fairness and community focus,” said Dr. Meg Doherty, WHO’s Director of HIV and STIs.
As of the end of 2024, an estimated 40.8 million people were living with HIV, with 65% residing in Africa. That year, HIV-related illnesses claimed 630,000 lives, and 1.3 million new infections were recorded, including 120,000 among children.
The virus continues to pose the greatest threat to vulnerable groups such as sex workers, men who have sex with men, transgender people, injection drug users, prisoners, and youth.
Despite ongoing challenges, progress continues: 31.6 million people received antiretroviral therapy in 2024, up from 30.3 million in 2023. This treatment is critical in preventing the progression of HIV into AIDS by preserving immune system function.
